CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective ways to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. We have a commercial product, PIXUVRI®, available in certain markets in Europe, as well as a diverse late-stage development pipeline that we believe will drive future growth of our company. We are headquartered in Seattle, Washington, with offices in London and Milan. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

  • Current Quote
  • Stock Chart
$2.12 - 0.06 (2.30%)
Day High:$2.20
Day Low:$2.11
06/02/154:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345

CTI Life Sciences Limited, Milan Branch
Laura Villa
T +1 39 02 94751572
T +1 206-272-4155 (U.S. only)

Recent News

May 30, 2015Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
Study demonstrates improvement in key disease measurements and disease-related symptoms with pacritinib treatment compared to best available therapy, regardless of platelet levels at the time of enrollment Treatment resulted in improvements in severe thrombocytopenia and severe anemia, eliminating the need for blood transfusions in a quarter of patients who were transfusion dependent at the time of enrollment CHICAGO, May 30, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASD... 
Printer Friendly Version
May 06, 2015CTI BioPharma Reports First Quarter 2015 Financial Results
- Late-breaking Abstract for Pacritinib Accepted for Presentation at ASCO - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, May 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2015. "After reporting positive top-line results from the PERSIST-1 Phase 3 clinical trial of pacritinib during the quarter, we have subsequently received positive feedback from a number of treat... 
Printer Friendly Version
Apr 23, 2015CTI BioPharma to Report First Quarter 2015 Financial Results on May 6, 2015
SEATTLE, April 23, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its first quarter 2015 financial results on Wednesday, May 6, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows: Wednesday, May 6 1:... 
Printer Friendly Version


May 06, 2015
Q1 2015 CTI BioPharma Corp Earnings Conference Call
Mar 12, 2015
Q4 2014 CTI BioPharma Corp Earnings Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed.